Payment overview · 2025
General Payments
$479.69
24 reported records · 11 companies
Healthcare provider profile · identity verified
Junias Desamour, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALTAMONTE SPRINGS, FL · NPI 1609890045
Verified facts
What the public records show
CMS Open Payments records show Junias Desamour, MD received $479.69 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Otezla.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.96 | 19.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.79 | 14.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $65.53 | 13.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.19 | 12.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $55.93 | 11.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.57 | 10.8% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.05 | 3.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.37 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.71 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.35 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.24 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $479.69 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $94.96 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.79 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.79 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $65.53 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.19 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $55.93 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.57 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 28 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 250 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 85 |
| Eliquis | Apixaban | 137 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 43 |
| Losartan Potassium | Losartan Potassium | 104 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 24 |
| Alprazolam | Alprazolam | 101 | 21 |
| Metformin Hcl | Metformin Hcl | 100 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 32 |
| Gabapentin | Gabapentin | 96 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 30 |
| Lisinopril | Lisinopril | 84 | 35 |
| Lactulose | Lactulose | 78 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 38 |
| Furosemide | Furosemide | 73 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 20 |
| Tramadol Hcl | Tramadol Hcl | 67 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | 12 |
| Trazodone Hcl | Trazodone Hcl | 63 | 13 |
| Lorazepam | Lorazepam | 56 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 25 |
| Donepezil Hcl | Donepezil Hcl | 55 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 11 |
| Carvedilol | Carvedilol | 54 | 25 |
| Meloxicam | Meloxicam | 53 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 31 |
| Mirtazapine | Mirtazapine | 50 | 17 |
| Prednisone | Prednisone | 50 | 21 |
| Levetiracetam | Levetiracetam | 48 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 16 |
| Finasteride | Finasteride | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 17 |
| Midodrine Hcl | Midodrine Hcl | 42 | 16 |
| Omeprazole | Omeprazole | 42 | 15 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Potassium Chloride | Potassium Chloride | 38 | 17 |
| Clonidine Hcl | Clonidine Hcl | 37 | 20 |
| Glipizide | Glipizide | 37 | 15 |
| Clonazepam | Clonazepam | 36 | 11 |
| Famotidine | Famotidine | 36 | 14 |
| Methocarbamol | Methocarbamol | 36 | 19 |
| Simvastatin | Simvastatin | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 34 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 34 | 16 |
| Montelukast Sodium | Montelukast Sodium | 34 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 16 |
| Risperidone | Risperidone | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Lidocaine | Lidocaine | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | 11 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Relistor | Methylnaltrexone Bromide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $479.69 · 24 records | AstraZeneca Pharmaceuticals LP | Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Korlym, MOUNJARO, NUZYRA, OTEZLA, PAXLOVID, REPATHA, REXULTI, TZIELD, XHANCE, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error